Global strategic, commercial, and creative engagement partner.
Combining our unique mix of consultation, creation, and activation expertise with the latest technology, we design and deliver tailored solutions that inspire lasting change
We are a group of more than 5,000 experts, working in more than 20 countries. A passionate, diverse team with global reach and local knowledge. Together, we partner with our clients to challenge conventional thinking, to empower people to make better health decisions and enhance treatment outcomes across the globe.
Navigate this carousel with the arrows.
Chief Delivery Platforms Officer
Chief People & Culture Officer
Chief Financial Officer
Sese is an experienced Commercial Analytics and Insight professional with cross industry expertise covering life sciences, financial services and retail apparel. Starting as an analyst at Redcats USA, and later working as a Senior Statistician at IQVIA, his background in manipulating data led to his success in leading business insights teams while at AstraZeneca. In these roles and organizations, Sese successfully led several commercial insight processes and teams and implemented enterprise-wide commercial effectiveness innovation initiatives. His expertise in narrowing in on data that builds powerful product and brand marketing programs, coupled with a passion for entrepreneurship drove him to create PROPENSITY4.
Prior to forming TCEG in 2016, Russ held strategic and leadership roles in a variety of blue-chip advertising agency groups including IPG, WPP and Havas. He is a member of The Marketing Group of Great Britain; Fellow of the RSA; EMBA advisor for Oxford Said Business School and recently voted Creativepool’s Creative Leader of the Year 2021. Russ is Chair of Trustees for Creative Mentor Network and Chair of the Advisory Board for Isla (industry sustainability body).
Nareda has more than 25 years’ experience in the Healthcare and Pharma industry in various leadership roles. Prior to working for Ashfield, Nareda worked in virtually all disease areas as the manager of the University of South Florida sub-specialty clinics for over 12 years as a Registered Nurse. Nareda’s vast clinical experience ranges from hematology, oncology, bone marrow transplant to endocrinology, nephrology, behavioral neuroscience and tertiary allergy and immunology. Nareda has been with Ashfield since 2008 and now oversees our US Patient Solutions business unit.
Mike leads Ashfield Engage’s US activities focused on HCP engagement which includes in-person, contact center, and omnichannel promotional sales and customer service activities. He is in his sixth year with Ashfield and has over 25 years of experience in commercial leadership roles. His most recent roles include VP, Global Commercial Excellence at Mylan, and VP Sales and Sales Operations at Valeritas. He spent 15 years with Sanofi in Marketing, Sales and Operational leadership roles. Mike has a BA from Lafayette College and an MBA from Penn State University.
Born in Argentina, Martin majored in Business Management and worked at Accenture for nine years. Martin moved to Japan in 2010 looking for adventure, did an MBA at Hitotsubashi University and upon graduation joined CMIC Holdings, Ashfield Engage’s strategic partners in Japan. Martin worked with Greg Flynn to establish the joint venture and transferred to CMIC Ashfield Co. Ltd. in 2014, holding roles in Corporate Planning, Strategy and BD. Martin officially joined Ashfield Engage in October 2020 as Japan President and VP Strategy. He is currently Regional President for Japan and Rest of World (at the moment Argentina and Brazil), as well as global VP Strategy.
Benjamin took on his latest role in June 2021 where he is responsible for the European businesses of Ashfield Engage. He has over ten years of general management experience at Ashfield in diverse positions leading smaller countries up to managing the biggest European country under Ashfield Engage. Before his career with Ashfield, Benjamin worked for ten years at McKesson Europe in positions such as Corporate Investor Relations, Corporate Industry Relations as well as Corporate M&A and Business Development.
With 18 years of experience in the healthcare and pharmaceutical industry, Amy has held various roles of increasing responsibility in Medical Affairs and Regulatory/Healthcare Compliance. As the current head of US Medical Affairs, she is responsible for developing, communicating and driving organizational strategy and leading the Ashfield Medical Affairs organization to success, with a prioritized focus on driving the strategy, design and execution of Medical Information and Medical Science Liaison programs. Prior to joining Ashfield, Amy spent more than ten years at Johnson & Johnson supporting the biopharmaceutical business in the areas of immunology, infectious diseases, vaccines, global public health, strategic customer group (market access), established products group, and the research and development areas.
Joining Ashfield in 2005 as a Regional Account Director in the UK, Greg has since worked with our teams across the UK, Japan and the US. He established and ran our joint venture in Japan before moving to the US in 2017 to lead Engage before his appointment as President of Engage in September 2019.
Learn from our experts! Explore content on topics from all of our specialist areas including: insight generation, medical affairs, experience design, patient solutions, sales and HCP promotion, and much more.
Inizio Engage conducted an independent market research study to explore the future of engagement with HCPs.
CASE STUDY (US) Combining tactics, insights, and business strategy drives significant growth in Women's Healthcare launch.
Supporting a new European division to launch brands in eight markets.
Client’s specialty product had a complicated oral therapy regimen requiring supplemental support to patients...
Leveraging our connected suite of capabilities, our experts will guide you through each pivotal moment in your asset’s lifecycle, creating tailored solutions that simplify the complex, unlock value, and enhance treatment outcomes.